[引用][C] O3–06–05: Sustained cognitive benefit in patients with mild cognitive impairment (MCI) upon prolonged treatment with CHF5074
J Ross, SK Sharma, A Chatterjee… - Alzheimer's & …, 2013 - Wiley Online Library
Background CHF5074 is a new microglial modulator that has been shown to prevent brain
plaque deposition and attenuate memory deficits in transgenic mouse models of AD. In man …
plaque deposition and attenuate memory deficits in transgenic mouse models of AD. In man …
[引用][C] O4‐11‐01: RELATIONSHIP BETWEEN CEREBROSPINAL FLUID (CSF) BIOMARKERS AND COGNITIVE PERFORMANCE OF PATIENTS WITH MILD …
BP Imbimbo, M Fernandez, L Giardino… - Alzheimer's & …, 2014 - Wiley Online Library
Background CHF5074 is a newly identified microglial modulator previously shown to lower
CSF levels of sCD40L and TNF-alpha in a 14-week, double-blind, placebo-controlled study …
CSF levels of sCD40L and TNF-alpha in a 14-week, double-blind, placebo-controlled study …
CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study
J Ross, S Sharma, J Winston, M Nunez… - Current Alzheimer …, 2013 - ingentaconnect.com
As neuroinflammation is an early event in the pathogenesis of Alzheimer's disease, new
selective antiinflammatory drugs could lead to promising preventive strategies. We …
selective antiinflammatory drugs could lead to promising preventive strategies. We …
[引用][C] P4‐390: Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer'S Patients Treated with T3D‐959: Interim Results of a Phase 2A …
J Didsbury - Alzheimer's & Dementia, 2016 - Wiley Online Library
Background T3D-959 is a small molecule, orally-delivered, brain-penetrating PPARδ/γ dual
nuclear receptor agonist acting to improve neuro-metabolic dysfunction in Alzheimer's …
nuclear receptor agonist acting to improve neuro-metabolic dysfunction in Alzheimer's …
CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid
V Porrini, A Lanzillotta, C Branca, M Benarese… - Neuroscience, 2015 - Elsevier
Activation of microglia associated with neuroinflammation and loss of phagocytic activity is
considered to play a prominent role in the pathogenesis of Alzheimer's disease (AD) …
considered to play a prominent role in the pathogenesis of Alzheimer's disease (AD) …
[引用][C] DT‐02‐05: A NOVEL THERAPEUTIC (NTRX‐07) TARGETING NEUROINFLAMMATION IN ALZHEIMER'S DISEASE IS UNDERGOING PHASE I TRIALS
M Naguib, T Giordano - Alzheimer's & Dementia, 2019 - Wiley Online Library
Background Neuroinflammation plays a central role in the pathogenesis of Alzheimer's
disease (AD). More than 25 genetic loci have been associated with the risk of developing …
disease (AD). More than 25 genetic loci have been associated with the risk of developing …
[PDF][PDF] O4–03–08: Efficacy and safety of MPC–7869 (R–flurbiprofen), a selective Aβ42–lowering agent, in Alzheimer's disease (AD): Results of a 12–month phase 2 …
GK Wilcock, SE Black, J Haworth, SB Hendrix… - Alzheimer's & …, 2006 - academia.edu
Background: RSG (PPAR agonist) is approved for type-2 diabetes treatment. Risner et al
reported cognitive endpoints from a 24-week, doubleblind, placebo-controlled monotherapy …
reported cognitive endpoints from a 24-week, doubleblind, placebo-controlled monotherapy …
[引用][C] P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified …
C Harrington, S Sawchak, C Chiang… - Alzheimer's & …, 2009 - Wiley Online Library
Background Two double-blind, placebo-controlled Phase III studies were conducted to
investigate the efficacy and safety of rosiglitazone-extended release tablets (RSG-XR) as an …
investigate the efficacy and safety of rosiglitazone-extended release tablets (RSG-XR) as an …
[引用][C] O4‐12‐04: EVP‐6124, a selective alpha‐7 partial agonist, has positive effects on cognition and clinical function in mild‐to‐moderate Alzheimer's disease …
D Hilt, M Gawryl, G Koenig, N Dgetluck… - Alzheimer's & …, 2012 - Wiley Online Library
Background Symptomatic therapy for Alzheimer's disease (AD) is presently limited to
AChEIs and Memantine. While these medications provide modest improvement in cognition …
AChEIs and Memantine. While these medications provide modest improvement in cognition …
Efficacy and safety of MLC601 in the treatment of mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled study
Abstract Background and Aim: Mild cognitive impairment (MCI) is characterized by declined
cognitive function greater than that expected for a person's age. The clinical significance of …
cognitive function greater than that expected for a person's age. The clinical significance of …